The estimated Net Worth of Louis Manzo is at least $262 Tysiąc dollars as of 21 February 2023. Mr. Manzo owns over 1,401 units of Capricor Therapeutics Inc stock worth over $261,664 and over the last 10 years he sold CAPR stock worth over $0. In addition, he makes $0 as Independent Director at Capricor Therapeutics Inc.
Louis has made over 8 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,401 units of CAPR stock worth $1,947 on 21 February 2023.
The largest trade he's ever made was buying 100,000 units of Capricor Therapeutics Inc stock on 16 March 2016 worth over $240,000. On average, Louis trades about 15,618 units every 155 days since 2015. As of 21 February 2023 he still owns at least 62,599 units of Capricor Therapeutics Inc stock.
You can see the complete history of Mr. Manzo stock trades at the bottom of the page.
Louis Manzo is Independent Director of CAPRICOR THERAPEUTICS, INC. . He was one of the initial investors in Capricor and joined the Capricor Board of Directors in 2006. Mr. Manzo is also a member of the Compensation Committee and the Nominating and Corporate Governance Committee. Mr. Manzo has been a prominent Baltimore entrepreneur for over three decades and has extensive experience in the area of finance. Mr. Manzo received his BS degree from the University of Notre Dame and his MBA from Harvard Business School. He served in the armed forces as an officer in the United States Navy. After completing his MBA at Harvard, Mr. Manzo joined, and in a few years became General Partner of, Baker, Watts & Co., a NYSE Member Firm. His experience there included being Director of Equity Research and later, the Head of Corporate Finance. During the 1980’s, Mr. Manzo started his own private investment firm, LVM Venture Partners. Beginning in 1989, Mr. Manzo became part of the founders group which helped a Johns Hopkins cardiologist fund his launching of a research center for preventive cardiology. Mr. Manzo remained as an advisor during the center’s formative years. His continued interest in preventive research included a major investment to research the use of protein modeling for early disease detection. Since 2002, he has been following and supporting research into the use of adult stem cells in the repair of spinal cord and heart damage. The list of private company boards, senior advisory roles, and charities that Mr. Manzo has been involved with over the years are numerous and varied, including: the Johns Hopkins Preventive Cardiology Center, a hospital center; Greater Baltimore Medical Center, a hospital; Goodwill Industries of Maryland, a non-profit organization; E.I.L Instruments, Inc., an instrument company; and Notre Dame University of Maryland, a private university.
Louis Manzo is 77, he's been the Independent Director of Capricor Therapeutics Inc since 2013. There are 1 older and 16 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
Louis's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... oraz Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: